Aspirin for primary prevention of vascular disease in people with diabetes.

Aspirin for primary prevention of vascular disease in people with diabetes.

Detalhes bibliográficos
Main Authors:	Haynes, R, Bowman, L, Armitage, J
Formato:	Journal article
Idioma:	English
Publicado em:	2009

Registos relacionados

Aspirin in the primary prevention of vascular disease Reply
Por: Baigent, C, et al.
Publicado em: (2009)

Aspirin in the primary prevention of vascular disease Reply
Por: Baigent, C, et al.
Publicado em: (2009)

Effects of aspirin for primary prevention in persons with diabetes mellitus
Por: Bowman, L, et al.
Publicado em: (2018)

Aspirin for primary prevention of cardiovascular disease in diabetes
Por: Ying Xing, et al.
Publicado em: (2019-07-01)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
Por: Bowman, L, et al.
Publicado em: (2017)

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
Por: Parish, S, et al.
Publicado em: (2022)

ASCEND-Eye: effects of aspirin on diabetic retinopathy
Por: Sammons, E, et al.
Publicado em: (2024)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
Por: Algra Ale, et al.
Publicado em: (2000-11-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
Por: Mant, J, et al.
Publicado em: (2021)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Por: Price, H, et al.
Publicado em: (2009)

Role of aspirin in primary prevention of cardiovascular disease
Por: Patrono, C, et al.
Publicado em: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
Por: VanWormer JJ, et al.
Publicado em: (2014-12-01)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Por: Baigent, C, et al.
Publicado em: (2009)

Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)
Por: Hamzah Khan, et al.
Publicado em: (2021-12-01)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Por: Hennekens, C, et al.
Publicado em: (1989)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
Por: Athena L. Huang, et al.
Publicado em: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
Por: Athena L. Huang, MD, et al.
Publicado em: (2023-09-01)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
Por: Fernández-de-Bobadilla Jaime, et al.
Publicado em: (2007-10-01)

Aspirin for prevention of cancer and cardiovascular disease.
Por: Rose, P, et al.
Publicado em: (2011)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
Por: Eleni Giannopoulou, et al.
Publicado em: (2024-12-01)

PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN DIABETES MELLITUS: THE ROLE OF ASPIRIN
Por: L. A. Strizhakov
Publicado em: (2012-04-01)

Prevention. Aspirin in primary prevention--good news and bad news.
Por: Hennekens, C, et al.
Publicado em: (2012)

Prevention: Aspirin in primary prevention-good news and bad news
Por: Hennekens, C, et al.
Publicado em: (2012)

The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
Por: Soo Hyun Kang, et al.
Publicado em: (2025-01-01)

Aspirin for the Primary Prevention of Vascular Ischemic Events: An Updated Systematic Review and Meta-analysis to Support Shared Decision-Making
Por: Chloë Laferrière, MD, et al.
Publicado em: (2023-12-01)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
Por: Hamzah Khan, et al.
Publicado em: (2022-08-01)

Aspirin for primary prevention of cardiovaascular events: what are the evidances?
Por: Yenny Yenny
Publicado em: (2019-08-01)

6 voices in 10 minutes: Aspirin in primary prevention
Por: Carlos Buso
Publicado em: (2020-11-01)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
Por: Xie W, et al.
Publicado em: (2019-09-01)

CLINICAL SIGNIFICANCE OF ASPIRIN RESISTANCE IN PATIENTS WITH CARDIO-VASCULAR DISEASES
Por: P. J. Dovgalevsky, et al.
Publicado em: (2016-01-01)

ASPIRIN FOR PRIMARY PREVENTION IN HIGH-RISK TYPE 2 DIABETES: INSIGHTS FROM THE ACCORD TRIAL
Por: Juliana H. Namutebi, MD, MS
Publicado em: (2024-09-01)

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
Por: Catalano, M, et al.
Publicado em: (2007)

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials
Por: Offer, A, et al.
Publicado em: (2019)

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
Por: Aung, T, et al.
Publicado em: (2017)

Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease
Por: Hadar Haim-Pinhas, et al.
Publicado em: (2022-10-01)

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.
Publicado em: (2005-12-01)

Cost‐Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease
Por: Tzeyu L. Michaud, et al.
Publicado em: (2015-12-01)

ASPIRIN IN THE PREVENTION OF ATHEROTHROMBOSIS AND CORONARY HEART DISEASE
Por: M. G. Bubnova
Publicado em: (2010-08-01)

Aspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factors
Por: Raffaele Bugiardini, et al.
Publicado em: (2020-10-01)

Hospital costs associated with adverse events in people with diabetes in the UK
Por: Keng, MJ, et al.
Publicado em: (2022)